S. Deeks and B. Walker, Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy, Immunity, vol.27, issue.3, pp.406-422, 2007.
DOI : 10.1016/j.immuni.2007.08.010

M. Re, M. Vignoli, G. Furlini, D. Gibellini, V. Colangeli et al., Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients, Journal of Clinical Virology, vol.21, issue.1, pp.81-90, 2001.
DOI : 10.1016/S1386-6532(00)00189-X

G. Rezza, V. Fiorelli, M. Dorrucci, M. Ciccozzi, A. Tripiciano et al., The Presence of Anti???Tat Antibodies Is Predictive of Long???Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIV???1 Seroconverters, The Journal of Infectious Diseases, vol.191, issue.8, pp.1321-1325, 2005.
DOI : 10.1086/428909

C. Van-baalen, O. Pontesilli, R. Huisman, A. Gerretti, M. Klein et al., Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS., Journal of General Virology, vol.78, issue.8, pp.1913-1921, 1997.
DOI : 10.1099/0022-1317-78-8-1913

A. Caputo, R. Gavioli, and B. Ensoli, Recent Advances in the Development of HIV-1 Tat-Based Vaccines, Current HIV Research, vol.2, issue.4, pp.357-76, 2004.
DOI : 10.2174/1570162043350986

V. Pollard and M. Malim, THE HIV-1 REV PROTEIN, Annual Review of Microbiology, vol.52, issue.1, pp.491-532, 1998.
DOI : 10.1146/annurev.micro.52.1.491

K. Arien and B. Verhasselt, HIV Nef: Role in Pathogenesis and Viral Fitness, Current HIV Research, vol.6, issue.3, pp.200-208, 2008.
DOI : 10.2174/157016208784325001

Y. Huang, L. Zhang, and D. Ho, Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection, J Virol, vol.69, pp.8142-8148, 1995.

D. Rhodes, L. Ashton, A. Solomon, A. Carr, D. Cooper et al., Characterization of Three nef-Defective Human Immunodeficiency Virus Type 1 Strains Associated with Long-Term Nonprogression, Journal of Virology, vol.74, issue.22, pp.10581-10589, 2000.
DOI : 10.1128/JVI.74.22.10581-10588.2000

V. Pancre, N. Delhem, Y. Yazdanpanah, A. Delanoye, M. Delacre et al., Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection, Vaccine, vol.25, issue.31, pp.5927-5964, 2007.
DOI : 10.1016/j.vaccine.2007.05.038

H. Zhang, Z. Qiu, and T. Li, HIV-1 nef specific cytotoxic T lymphocyte responses in long-term nonprogressors and AIDS patients], Zhonghua Yi Xue Za Zhi, vol.84, pp.1973-1979, 2004.

W. Dyer, J. Zaunders, F. Yuan, B. Wang, J. Learmont et al., Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection, Retrovirology, vol.5, issue.1, p.112, 2008.
DOI : 10.1186/1742-4690-5-112

V. Roman and M. Robert-guroff, Adenoviruses as vectors for HIV vaccines, AIDS Rev, vol.5, pp.178-85, 2003.

M. Robert-guroff, Replicating and non-replicating viral vectors for vaccine development, Current Opinion in Biotechnology, vol.18, issue.6, pp.546-56, 2007.
DOI : 10.1016/j.copbio.2007.10.010

F. Lemiale, W. Kong, L. Akyurek, X. Ling, Y. Huang et al., Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System, Journal of Virology, vol.77, issue.18, pp.10078-87, 2003.
DOI : 10.1128/JVI.77.18.10078-10087.2003

J. Fu, T. Chen, L. Casimiro, D. Davies, M. Evans et al., Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity, Nature, vol.415, pp.331-336, 2002.

T. Mast, L. Kierstead, S. Gupta, A. Nikas, E. Kallas et al., International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials, Vaccine, vol.28, issue.4, pp.950-957, 2010.
DOI : 10.1016/j.vaccine.2009.10.145

S. Buchbinder, D. Mehrotra, A. Duerr, D. Fitzgerald, R. Mogg et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial, The Lancet, vol.372, issue.9653, pp.1881-93, 2008.
DOI : 10.1016/S0140-6736(08)61591-3

O. Yang, Retracing our STEP towards a successful CTL-based HIV-1 vaccine, Vaccine, vol.26, issue.25, pp.3138-3179, 2008.
DOI : 10.1016/j.vaccine.2008.02.027

L. Patterson and M. Robert-guroff, Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development, Expert Opinion on Biological Therapy, vol.86, issue.9, pp.1347-63, 2008.
DOI : 10.1128/JVI.80.10.4858-4867.2006

K. Schoenly and D. Weiner, Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business", Journal of Virology, vol.82, issue.7, pp.3166-80, 2008.
DOI : 10.1128/JVI.01634-07

Y. Dai, E. Schwarz, D. Gu, W. Zhang, N. Sarvetnick et al., Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression., Proceedings of the National Academy of Sciences, vol.92, issue.5, pp.1401-1406, 1995.
DOI : 10.1073/pnas.92.5.1401

K. Laethem, K. Beuselinck, S. Van-dooren, D. Clercq, E. Desmyter et al., Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin, Journal of Virological Methods, vol.70, issue.2, pp.153-66, 1998.
DOI : 10.1016/S0166-0934(97)00178-X

O. Suptawiwat, R. Sutthent, T. Lee, and P. Auewarakul, Intragenic HIV-1 env sequences that enhance gag expression, Virology, vol.309, issue.1, pp.1-9, 2003.
DOI : 10.1016/S0042-6822(02)00084-3
URL : http://doi.org/10.1016/s0042-6822(02)00084-3

R. Sarrami-forooshani, S. Das, F. Sabahi, A. Adeli, R. Esmaeili et al., Molecular analysis and phylogenetic characterization of HIV in Iran, Journal of Medical Virology, vol.383, issue.7, pp.853-63, 2006.
DOI : 10.1002/jmv.20634

A. Buckle and N. Hogg, Human memory T cells express intercellular adhesion molecule-1 which can be increased by interleukin 2 and interferon-??, European Journal of Immunology, vol.141, issue.2, pp.337-378, 1990.
DOI : 10.1002/eji.1830200216

T. Scriba, J. Zur-megede, R. Glashoff, F. Treurnicht, S. Barnett et al., Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences, Vaccine, vol.23, issue.9, pp.1158-69, 2005.
DOI : 10.1016/j.vaccine.2004.08.026

I. Demirhan, A. Chandra, F. Mueller, H. Muller, P. Biberfeld et al., Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma, J Hum Virol, vol.3, pp.137-180, 2000.

M. Re, D. Gibellini, G. Furlini, M. Vignoli, and F. , Relationships between the presence of anti-Tat antibody , DNA and RNA viral load, New Microbiol, vol.24, pp.207-222, 2001.

P. Mooij and J. Heeney, Rational development of prophylactic HIV vaccines based on structural and regulatory proteins, Vaccine, vol.20, issue.3-4, pp.304-325, 2001.
DOI : 10.1016/S0264-410X(01)00373-5

E. Rollman, A. Brave, A. Boberg, G. Lsaguliants, and M. , The rationale behind a vaccine based on multiple HIV antigens, Microbes and Infection, vol.7, pp.1414-1437, 2005.
DOI : 10.1016/j.micinf.2005.07.017

E. Gabitzsch, Y. Xu, L. Yoshida, J. Balint, A. Amalfitano et al., Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity, Vaccine, vol.27, issue.46, pp.6394-6402, 2009.
DOI : 10.1016/j.vaccine.2009.06.028

J. Zhao, R. Voltan, B. Peng, A. Davis-warren, V. Kalyanaraman et al., Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag, Virology, vol.342, issue.1, pp.1-12, 2005.
DOI : 10.1016/j.virol.2005.07.016

R. Florese, K. Van-rompay, K. Aldrich, D. Forthal, G. Landucci et al., Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge, The Journal of Immunology, vol.177, issue.6, pp.4028-4064, 2006.
DOI : 10.4049/jimmunol.177.6.4028

M. Maggiorella, L. Sernicola, F. Crostarosa, R. Belli, M. Pavone-cossut et al., Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection, Journal of Medical Primatology, vol.3, issue.4-5, pp.180-94, 2007.
DOI : 10.1126/science.1076185

B. Ensoli, V. Fiorelli, F. Ensoli, A. Cafaro, F. Titti et al., Candidate HIV-1 Tat vaccine development: from basic science to clinical trials, AIDS, vol.20, issue.18, pp.2245-61, 2006.
DOI : 10.1097/QAD.0b013e3280112cd1

D. Casimiro, L. Chen, T. Fu, R. Evans, M. Caulfield et al., Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene, Journal of Virology, vol.77, issue.11, pp.6305-6318, 2003.
DOI : 10.1128/JVI.77.11.6305-6313.2003

D. Barouch, M. Pau, J. Custers, W. Koudstaal, S. Kostense et al., Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity, The Journal of Immunology, vol.172, issue.10, pp.6290-6297, 2004.
DOI : 10.4049/jimmunol.172.10.6290

V. Arora, B. Fredericksen, and J. Garcia, Nef: agent of cell subversion, Microbes and Infection, vol.4, issue.2, pp.189-99, 2002.
DOI : 10.1016/S1286-4579(01)01527-1